Cargando…

Correction to: Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis

Detalles Bibliográficos
Autores principales:	Abu-Sbeih, Hamzah, Herrera, Lauren Nicholas, Tang, Tenglong, Altan, Mehmet, Chaftari, Anne-Marie, Okhuysen, Pablo C., Jenq, Robert R., Wang, Yinghong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918684/ https://www.ncbi.nlm.nih.gov/pubmed/31847892 http://dx.doi.org/10.1186/s40425-019-0832-5

Ejemplares similares

Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis
por: Abu-Sbeih, Hamzah, et al.
Publicado: (2019)

Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury
por: Abu-Sbeih, Hamzah, et al.
Publicado: (2019)

Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson
por: Wang, Yinghong, et al.
Publicado: (2018)

Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis
por: Abu-Sbeih, Hamzah, et al.
Publicado: (2018)

Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis
por: Abu-Sbeih, Hamzah, et al.
Publicado: (2019)

Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study
por: Abu-Sbeih, Hamzah, et al.
Publicado: (2018)

Diarrhea and colitis related to immune checkpoint inhibitor and BRAF/MEK inhibitor therapy
por: Kuang, Andrew G., et al.
Publicado: (2023)

Clinical characteristics of colitis induced by taxane-based chemotherapy
por: Chen, Ellie, et al.
Publicado: (2020)

Clinical Features and Management of Acute and Chronic Radiation-Induced Colitis and Proctopathy
por: Abu-Sbeih, Hamzah, et al.
Publicado: (2023)

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis
por: Abu-Sbeih, Hamzah, et al.
Publicado: (2019)

Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment
por: Abu-Sbeih, Hamzah, et al.
Publicado: (2019)

Cytomegalovirus infection among patients with cancer receiving immune checkpoint inhibitors
por: Panneerselvam, Kavea, et al.
Publicado: (2022)

Correction: Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis
por: Reddy, Haritha G., et al.
Publicado: (2018)

Immune checkpoint inhibitor-induced diarrhea/colitis: Endoscopic and pathologic findings
por: Nishida, Tsutomu, et al.
Publicado: (2019)

1410. Isoniazid Therapy for Latent Tuberculosis Infection in Patients with Cancer Treated with Checkpoint Inhibitors Immunotherapy
por: Malek, Alexandre, et al.
Publicado: (2021)

Gastrointestinal toxic effects in patients with cancer receiving platinum-based therapy
por: Abu-Sbeih, Hamzah, et al.
Publicado: (2020)

Implementing an immunotherapy toxicity (IOTOX) GI service improves outcomes in patients with immune-mediated diarrhea and colitis
por: Saji, Alice, et al.
Publicado: (2022)

Clostridioides difficile infection in cancer patients receiving immune checkpoint inhibitors
por: Vasavada, Shaleen, et al.
Publicado: (2022)

Diffuse Metastatic Melanoma in the GI Lumen Following Immune Checkpoint Inhibitor Colitis Treatment
por: Sperling, Gabriel, et al.
Publicado: (2022)

Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis
por: Badran, Yousef R, et al.
Publicado: (2023)

Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab
por: Zhang, Hao Chi, et al.
Publicado: (2019)

1100. Characterization of Enteropathogenic Escherichia coli (EPEC) in Cancer Patients With Diarrhea
por: Okhuysen, Pablo, et al.
Publicado: (2018)

Severe Inflammatory Colitis Related to Encorafenib and Binimetinib following Immune Checkpoint Inhibitor Therapy
por: Issac, Aaron G., et al.
Publicado: (2022)

Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy
por: Rajha, Eva, et al.
Publicado: (2019)

Severe Diarrhea in the Setting of Immune Checkpoint Inhibitors
por: Kuo, Jean R., et al.
Publicado: (2018)

Colon Adenoma After Diagnosis of Immune Checkpoint Inhibitor-mediated Colitis
por: Machado, Antonio Pizuorno, et al.
Publicado: (2023)

1539. Diagnosis of Yersinia enterocolitica in Cancer Patients With Diarrhea in the Era of Molecular Diagnostics for Gastrointestinal Infections
por: Wang, Elizabeth, et al.
Publicado: (2018)

Gut microbiome and checkpoint inhibitor colitis
por: Sehgal, Kanika, et al.
Publicado: (2021)

Checkpoint Inhibitor-Induced Colitis: An Update
por: Losurdo, Giuseppe, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor-Induced Colitis Presenting As Lymphocytic Colitis
por: Khan, Jaffar, et al.
Publicado: (2021)

Correction: Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis
Publicado: (2021)

Microbiome influencers of checkpoint blockade–associated toxicity
por: Wang, Yinghong, et al.
Publicado: (2023)

Correction: Chronic immune checkpoint inhibitor pneumonitis
Publicado: (2020)

Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis
por: Reddy, Haritha G., et al.
Publicado: (2018)

Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis
por: Westdorp, Harm, et al.
Publicado: (2021)

Refractory Checkpoint Inhibitor Colitis Responsive to Ustekinumab
por: Perez Del Nogal, Genesis, et al.
Publicado: (2022)

Focal Active Colitis Presented With Chronic Diarrhea
por: Mandzhieva, Bayarmaa, et al.
Publicado: (2020)

Immune checkpoint inhibitors induced colitis, stay vigilant: A case report
por: Abu Khalaf, Suha, et al.
Publicado: (2020)

Diagnosis of Yersinia enterocolitica Infection in Cancer Patients With Diarrhea in the Era of Molecular Diagnostics for Gastrointestinal Infections
por: Wang, Elizabeth Wenqian, et al.
Publicado: (2019)

Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease
por: Abu-Sbeih, Hamzah, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9k6gbjnvq8cqedlgntg6e7ors7